Efficacy of infliximab for induction and maintenance of remission in intestinal Behcet's disease
Efficacy of infliximab for induction and maintenance of remission in intestinal Behcet's disease
复制标题
DOI：
10.1002/ibd.20457
复制
发表时间：
2008-09-01
影响因子：
4.9
通讯作者：
Hibi, Toshifumi
中科院分区：
文献类型：
--
作者：
Naganuma, Makoto;Sakuraba, Atsushi;Hibi, Toshifumi
背景资料：肠道白塞氏病（BD）是一种以肠道炎症为特征的疾病，伴有胃肠道症状的圆形和椭圆形溃疡。英夫利西单抗对诱导病情缓解有一定疗效，但对维持病情缓解的疗效尚不清楚。所有患者均为激素依赖型，免疫抑制剂难治性; 3例患者接受6-巯基嘌呤治疗，1例患者接受硫唑嘌呤治疗。结果：4例患者经英夫利昔单抗治疗后缓解，所有患者经英夫利昔单抗治疗后均维持缓解，缓解持续时间约3年。另外2例回肠溃疡患者需要手术;然而，1例患者在手术后2年内通过预定的hifliximab治疗维持了缓解。结论：英夫利西单抗似乎为暴发性肠道BD提供了诱导和维持缓解的选择，尽管需要随机对照试验。
Background: Intestinal Behcet disease (BD) is characterized by intestinal inflammation With round and oval ulcers associated with gastrointestinal symptoms. Although several cases have been reported that infliximab is effective For induction of remission, the efficacy of infliximab For maintaining remission is unknown.Methods: Six cases with fulminant intestinal BD were treated with infliximab. All patients were steroid-dependent and refractory to immunosuppressants; 3 patients were treated with 6-mercaptopurine, I patient with azathioprine. I patient with cyclosporine A, and I patient with methotrexate.Results: Four patients achieved remission by infliximab and all of these patients maintained remission With scheduled treatments of infliximab, With the Inogest duration of remission being about 3 years. Another 2 patients with ileal Ulceration required Surgery; however, I patient has maintained remission by scheduled treatment of hifliximab for 2 years after surgery.Conclusions: Infliximab appears to offer an option for fulminant intestinal BD to induce and Maintain remission, although a randomized control trial is needed.